PRKG1 and cardiac hypertrophy: We also revealed the potential mechanism underlying the therapeutic effects of the TP-10@CaP-CTP nanoparticles, showing that they attenuate cardiac hypertrophy and cardiac fibrosis via the cAMP/AMPK and cGMP/PKG signalling pathways, respectively.